In a phase III trial reported in The New England Journal of Medicine, Johnson et al found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy vs omission of bleomycin (AVD) after negative interim PET-CT (positron-emission tomography–computed...
In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...
The phase III European MCL Younger trial has shown that adding high-dose cytarabine to immunochemotherapy prior to autologous stem cell transplantation (ASCT) increased the time to treatment failure among patients with mantle cell lymphoma (MCL) aged ≤ 65 years. The results were reported by...
In an analysis of the observational data base of the Center for International Blood and Marrow Transplant Research reported in the Journal of Clinical Oncology, Ghosh et al found that lymphoma patients undergoing reduced-intensity conditioning had similar outcomes with related-donor haploidentical...
In long-term follow-up of a European trial reported by Demeestere et al in the Journal of Clinical Oncology, gonadotropin-releasing hormone (GnRH) agonist treatment during chemotherapy in young women with lymphoma was not associated with reduced premature ovarian failure or an improved pregnancy...
Crump et al found no disease-free survival benefit of maintenance therapy with the selective protein kinase Cb (PKCb) inhibitor enzastaurin in patients with diffuse large B-cell lymphoma (DLBCL) who were in complete remission and at high risk of relapse after first-line chemotherapy, according to a ...
In a phase III trial (EORTC 20012 Intergroup Trial) reported by Carde et al in the Journal of Clinical Oncology, similar outcomes were achieved with eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs four cycles each of escalated BEACOPP (bleomycin, etoposide, doxorubicin,...
In a study reported in Modern Pathology, Cani et al used next-generation sequencing to identify actionable mutations in orbital and ocular adnexal lymphomas, finding frequent alterations in MYD88 and chromatin modifiers. Study Details The study involved next-generation sequencing of 36...
In a study reported in the Journal of Clinical Oncology, Roemer et al identified PD-L1 (programmed cell death ligand 1) and PD-L2 genetic alterations in patients with classic Hodgkin lymphoma, finding that 9p24.1 amplification was common and associated with advanced-stage disease and poorer...
In a French phase III trial reported in The Lancet, Ribrag et al showed that adding rituximab (Rituxan) to dose-dense chemotherapy improved event-free survival among adults with Burkitt lymphoma. Study Details In the open-label trial, 260 patients were randomized between October 2004 and...
In a phase II US Intergroup trial (Southwest Oncology Group S0816) reported in the Journal of Clinical Oncology, Press et al found that early interim fluorodeoxyglucose positron-emission tomography (FDG-PET) to guide response-adapted therapy resulted in progression-free survival substantially...
Hoster et al found that Ki67 index had greater prognostic value than cytology or growth pattern in mantle cell lymphoma, based on data from European Mantle Cell Lymphoma Network randomized trials reported in the Journal of Clinical Oncology. A modified combination of Ki67 index and Mantle Cell...
The phase II portion of the Italian HD0801 study suggests that treatment based on positron-emission tomography (PET) performed early in first-line therapy for advanced Hodgkin lymphoma may improve outcome in patients at risk of first-line treatment failure. Zinzani et al reported their findings in...
In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...
In a study reported in The New England Journal of Medicine, Armstrong et al found that late mortality decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. The reduction is consistent with efforts during recent decades to modify treatment with ...
In a Swedish study reported in the Journal of Clinical Oncology, Weibull et al found that pregnancy did not appear to increase the risk of subsequent relapse in women with Hodgkin lymphoma in remission. Study Details The study included data from Swedish health-care registers and medical records...
In the long-term follow-up of the Italian HD2000 trial reported by Merli et al in the Journal of Clinical Oncology, no significant differences in overall or progression-free survival were observed after 10 years among patients with previously untreated advanced Hodgkin lymphoma receiving ABVD...
In the phase III HELIOS trial reported in The Lancet Oncology, Chanan-Khan et al found that the addition of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic ...
In the phase III HELIOS trial, reported in The Lancet Oncology, Chanan-Khan et al found that adding the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic leukemia or...
As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...
In a letter to The New England Journal of Medicine, Hamadani et al describe near-complete and complete responses with the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) in two heavily pretreated patients with classic Hodgkin lymphoma. Patient 1 The first patient was a 28-year-old...
In a Danish-Swedish population-based study reported in the Journal of Clinical Oncology, El-Galaly et al found that routine imaging for diffuse large B-cell lymphoma in patients in first complete remission does not improve post-treatment survival. Study Details The study included 525 Danish and...
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
In a study reported in The Lancet Oncology, Pastore et al found that the addition of mutation status of seven genes to the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status produced a clinicogenetic model (m7-FLIPI) with high ...
In a study reported in the Journal of Clinical Oncology, Vargo et al found that use of consolidative radiotherapy, which continues to decline, is associated with a survival benefit compared with multiagent chemotherapy alone in patients with early-stage diffuse large B-cell lymphoma. Study Details ...
In a study reported in the Journal of Clinical Oncology, Scott et al found that the digital gene expression–based Lymph2Cx assay produced concordant cell of origin assignments in formalin-fixed paraffin-embedded tissue biopsies from patients with diffuse large B-cell lymphoma and showed high...
Risk for melanoma has been found to be increased in non-Hodgkin lymphoma (NHL) survivors. In a study reported in the Journal of Clinical Oncology, Lam et al found that T-cell–activating autoimmune diseases and fludarabine use were associated with an increased melanoma risk among patients with ...
As reported by Eichenauer and colleagues in the Journal of Clinical Oncology, an analysis of long-term outcomes suggests that involved-field radiotherapy may be the best treatment option in patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma. Study Details The study involved...
In an analysis of the German Hodgkin Study Group HD12 and HD15 trials reported in the Journal of Clinical Oncology, Haverkamp et al found that discontinuation of bleomycin and vincristine due to drug-specific adverse effects did not affect efficacy of BEACOPP (bleomycin, etoposide,...
In the phase II BELIEF trial reported in the Journal of Clinical Oncology, O’Connor et al found that the pan–histone deacetylase inhibitor belinostat (Beleodaq) produced durable responses in patients with relapsed/refractory peripheral T-cell lymphoma. The study supported the U.S. Food...
In an analysis from the National LymphoCare Study reported in the Journal of Clinical Oncology, Casulo et al found that disease progression within 2 years of diagnosis was associated with increased mortality risk after first-line R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin,...
In a phase II Intergroup trial (SWOG 1108) reported in the Journal of Clinical Oncology, Barr et al found that the aurora A kinase inhibitor alisertib produced responses in patients with relapsed/refractory peripheral T-cell non-Hodgkin lymphoma. Aurora A kinase is upregulated in highly...
In an analysis of Children’s Oncology Group (COG) trials reported in the Journal of Clinical Oncology, Chow et al found that dexrazoxane use did not appear to be associated with poorer survival among pediatric patients with leukemia or lymphoma in long-term follow-up. Study Details The...
As reported in the Journal of Clinical Oncology by Advani et al, a subset analysis of the phase III North American Intergroup E2496 trial showed no significant difference in failure-free or overall survival between ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy vs the...
In a German study reported in The Lancet Oncology, Brämswig et al found that women treated for Hodgkin lymphoma during childhood or adolescence had a good prognosis for achieving parenthood. Study Details This prospective longitudinal study included 467 female patients aged < 18 years at...
In a UK phase III RAPID trial reported in The New England Journal of Medicine, Radford et al compared no further treatment vs involved-field radiotherapy in patients with early-stage Hodgkin lymphoma who had negative positron emission tomography (PET) findings after 3 cycles of doxorubicin,...
In a study reported in The Lancet Oncology, Roschewski et al found that interim monitoring of circulating tumor DNA in patients with diffuse large B-cell lymphoma distinguished more and less rapid progression and that surveillance monitoring identified recurrence well before clinical evidence was...
In a single-institution study reported in the Journal of the National Cancer Institute, Matasar et al found that Hodgkin lymphoma patients treated during adulthood were at increased risk of all-cause and second primary malignancy mortality compared with SEER (Surveillance, Epidemiology, and...
In an analysis reported in the Journal of Clinical Oncology, Kelly et al found that low baseline serum vitamin D levels are associated with poorer progression-free and overall survival in patients with previously untreated follicular lymphoma. Study Details The study involved analysis of data...
In the phase III AETHERA trial reported in The Lancet, Moskowitz et al found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs placebo in patients with Hodgkin lymphoma at risk for relapse or...
In a phase II study reported in The Lancet Oncology, Moskowitz et al found that a salvage strategy involving brentuximab vedotin (Adcetris) treatment followed by 18F-fluorodeoxyglucose positron-emission tomography (PET) and augmented ifosfamide, carboplatin, and etoposide (ICE) in PET-positive...
In a phase III trial reported in The New England Journal of Medicine, Robak et al found that VR-CAP, a regimen replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone), significantly improved progression-free...
In an analysis among patients in the Eastern Cooperative Oncology Group (ECOG) E4402 trial (RESORT) reported in the Journal of Clinical Oncology, Wagner et al found no difference in anxiety or health-related quality of life in patients with low–tumor burden non-Hodgkin lymphoma who received...
In a study reported in the Journal of Clinical Oncology, Olszewski et al found that numerous factors affected use of combined-modality therapy vs chemotherapy alone in early-stage Hodgkin lymphoma, including sex, race, insurance, and distance to treatment facility. Study Details The study...
In a European open-label noninferiority trial (German Hodgkin Study Group [GHSG)] HD13) reported in The Lancet, Behringer et al found poorer outcomes with omission of dacarbazine or bleomycin from treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with...
In a Chinese study reported in JAMA, Huang et al found that treatment with entecavir (guanosine analog reverse transcriptase inhibitor) reduced hepatitis B virus (HBV)-related hepatitis and HBV reactivation compared with lamivudine (cytidine analog reverse transcriptase inhibitor) in HBV-positive...
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the PD-1 pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of PD-L1 and PD-L2 and promoting...
In an analysis of the French phase III LNH 03-2B trial reported in the Journal of Clinical Oncology, Molina et al found that germinal center B-cell–like vs non–germinal center B-cell–like subclassification of diffuse large B-cell lymphoma according to the Hans algorithm was...
In the phase II SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group reported in the Journal of Clinical Oncology, Pfreundschuh et al found that extended rituximab (Rituxan) exposure in patients aged > 60 years with poor-prognosis diffuse large B-cell lymphoma was...
In a prospective Chinese study reported in the Journal of Clinical Oncology, Seto et al found a 2-year rate of hepatitis B virus (HBV) reactivation of 41.5% in hepatitis B surface antigen (HBsAg)-negative and anti–hepatitis B core antigen antibody (anti-HBc)–positive patients receiving...